Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Several technologies for hemoglobinopathies are being transferred to commercial partners
New study presents a human-relevant stress model for assessing potential therapeutics
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Subscribe To Our Newsletter & Stay Updated
